medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2022, Número 4

<< Anterior

Cardiovasc Metab Sci 2022; 33 (4)


Declaración de Consenso del Colegio Mexicano de Cardiología Intervencionista y Terapia Endovascular sobre el tratamiento coronario percutáneo con balón recubierto de fármaco. La declaración de consenso COMECITE

Moguel-Ancheita R, Olvera-Ruiz R, Moreno-Buenrostro J, Ramos-Cházaro E, Lozoya-Morales JJ, Bautista-López GR, Bayardo-Solórzano HV, Castillo-Gutiérrez MA, Picos-Bovio EM, Beltrán-Nevárez O, Muñoz-Beltrán LG, Cabrera-Arroyo CG

Idioma: Inglés [English version]
Referencias bibliográficas: 67
Paginas: 196-209
Archivo PDF: 297.33 Kb.


RESUMEN

La intervención coronaria percutánea (ICP) es actualmente el método de revascularización prevalente durante los últimos 40 años debido a su eficacia, baja tasa de complicaciones y mínima invasión, con el inconveniente de la restenosis. La estrategia dominante para mejorar la ICP para obtener beneficios a largo plazo es la utilización de stents liberadores de fármacos, aunque la tasa actual de restenosis intrastent es ≈10%, aparte de otros inconvenientes como la inserción de cuerpo extraño, riesgo de trombosis, hemorragia en pacientes de alto riesgo, potencial de atrapamiento de ramas y posibilidad de múltiples capas de metal después del tratamiento de la restenosis intrastent. El balón recubierto de fármaco puede reducir la restenosis sin dejar un cuerpo extraño ni agregar capas de metal, su uso está respaldado por declaraciones de consenso de grupos de expertos y actualizaciones de publicaciones de informes durante casi una década. El presente artículo es de la declaración del Colegio Mexicano de Cardiología Intervencionista y Terapia Endovascular (COMECITE) con respecto a la utilización actual del balón medicado coronario y recomendaciones en restenosis intrastent, vasos pequeños, bifurcaciones, descendente anterior izquierda/coronaria principal izquierda e infarto agudo de miocardio.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous coronary intervention. [Updated 2021 Jan 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available in: https://www.ncbi.nlm.nih.gov/books/NBK556123/

  2. Piccolo R, Bonaa KH, Efthimiou O, Varenne O et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019; 393 (10190): 2503-2510.

  3. Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv. 2019; 12 (8): e007023.

  4. Moreno R, Fernández C, Alfonso F, Hernández R et al. Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J Am Coll Cardiol. 2004; 43 (11): 1964-1972.

  5. Durante A, Laforgia PL. Drug-coated balloons and coronary bifurcation lesions. EMJ Int Cardiol. 2017; 5: 80-84.

  6. Di Gioia G, Sonck J, Ferenc M, Chen SL et al. Clinical outcomes following coronary bifurcation pci techniques: a systematic review and network meta-analysis comprising 5,711 patients. JACC Cardiovasc Interv. 2020; 13 (12): 1432-1444.

  7. Kleber FX, Mathey DG, Rittger H, Scheller B; German Drug-eluting Balloon Consensus Group. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011; 7 Suppl K: K125-128.

  8. Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020; 13 (12): 1391-1402.

  9. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available in: www.cochrane-handbook.org

  10. Shea BJ, Reeves BC, Wells G, Thuku M et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358: j4008.

  11. Thangaratinam S, Redman CWE. The Delphi technique. Obstet Gynaecol. 2005; 7: 120-125.

  12. ICMJE. Defining the role of authors and contributors. Available in: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

  13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414): 557-560.

  14. Hoffman JIE. Basic biostatistics for medical and biomedical practitioners. 2nd edition. Chapter 36. Meta-analysis. New York: Elsevier; 2019. pp. 621-629.

  15. Egger M, Smith GD. Meta-Analysis. Potentials and promise. BMJ. 1997; 315 (7119): 1371-1374.

  16. Wanha W, Bil J, Januszek R, Gilis-Malinowska N et al. Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis (DEB-Dragon-Registry). Circ Cardiovasc Interv. 2021; 14: e010868.

  17. Her AY, Yuan SL, Jun EJ, Bhak Y et al. Drug-coated balloon treatment for nonsmall de novo coronary artery disease: angiographic and clinical outcomes. Coron Artery Dis. 2021; 32 (6): 534-540.

  18. Megaly M, Rofael M, Saad M, Shishehbor M, Brilakis ES. Outcomes with drug-coated balloons for treating the side branch of coronary bifurcation lesions. J Invasive Cardiol. 2018; 30 (11): 393-399.

  19. Zheng Y, Li J, Wang L, Yu P et al. Effect of drug-coated balloon in side branch protection for de novo coronary bifurcation lesions: a systematic review and meta-analysis. Front Cardiovasc Med. 2021; 8: 758560.

  20. Corballis NH, Paddock S, Gunawardena T, Merinopoulos I et al. Drug coated balloons for coronary artery bifurcation lesions: A systematic review and focused meta-analysis. PLoS One. 2021; 16 (7): e0251986.

  21. Jing QM, Zhao X, Han YL et al. A drug-eluting Balloon for the trEatment of coronarY bifurcatiON lesions in the side branch: a prospective multicenter ranDomized (BEYOND) clinical trial in China. Chin Med J (Engl). 2020; 133 (8): 899-908.

  22. Burzotta F, Lassen JF, Lefevre T, Banning AP et al. Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club. EuroIntervention. 2021; 16 (16): 1307-1317.

  23. De Almeida Prado GF, Guedes BC, Pereira AGM et al. Efficacy of drug-eluting balloon in the treatment of ostial left anterior descending artery in-stent restenosis. Rev Bras Cardiol Invasiva. 2014; 22 (2): 183-187.

  24. Yee ST, Azhari R. TCTAP C-076 drug coated balloon of native ostial left anterior descending. J Am Coll Cardiol. 2021; 77 (14_Supplement): S173-S174.

  25. Shetty R, Ganiga Sanjeeva NC, Agarwal S, Doshi M, Sojitra P. Unprotected distal left main bifurcation drug eluting stent restenosis: first successful experience with simultaneous kissing balloon dilatation using sirolimus coated balloon. Cardiovasc Diagn Ther. 2015; 5 (6): 484-487.

  26. Maximkin D, Shugushev Z, Chepurnoy A, Gitelzon E, Faybushevich A. Drug-eluting balloon catheters in the treatment of left main coronary artery bifurcation lesions: 4-years follow-up. Eur Heart J. 2021; 42 (Suppl 1): ehab724.1434.

  27. Kitani S, Igarashi Y, Tsuchikane E, Nakamura S et al. Efficacy of drug-coated balloon angioplasty after directional coronary atherectomy for coronary bifurcation lesions (DCA/DCB registry). Catheter Cardiovasc Interv. 2021; 97 (5): E614-E623.

  28. Hu H, Shen L. Drug-coated balloons in the treatment of acute myocardial infarction (Review). Exp Ther Med. 2021; 21 (5): 464.

  29. Vos NS, Fagel ND, Amoroso G, Herrman JR et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv. 2019; 12 (17): 1691-1699.

  30. Hao X, Huang D, Wang Z, Zhang J et al. Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. J Cardiothorac Surg. 2021; 16 (1): 178.

  31. Scheller B, Ohlow MA, Ewen S, Kische S et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020; 15 (17): 1527-1533.

  32. Rhee TM, Lee JM, Shin ES, Hwang D et al. Impact of optimized procedure-related factors in drug-eluting balloon angioplasty for treatment of in-stent restenosis. JACC Cardiovasc Interv. 2018; 11 (10): 969-978.

  33. Shin ES, Bang LH, Jun EJ, Her AY et al. Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion. Cardiol J. 2021; 28 (4): 615-622.

  34. Bech GJ, Pijls NH, De Bruyne B et al. Usefulness of fractional flow reserve to predict clinical outcome after balloon angioplasty. Circulation. 1999; 99 (7): 883-888.

  35. Iijima R, Kougame N, Hara H, Moroi M, Nakamura M. Clinical outcomes of drug-coated balloons in coronary artery disease unsuitable for drug-eluting stent implantation. Circ J. 2018; 82 (8): 2025-2031.

  36. Ybarra LF, Dandona S, Daneault B, Rinfret S. Drug-coated balloon after subintimal plaque modification in failed coronary chronic total occlusion percutaneous coronary intervention: A novel concept. Catheter Cardiovasc Interv. 2020; 96 (3): 609-613.

  37. Albertal M, Van Langenhove G, Regar E, Kay IP et al. Uncomplicated moderate coronary artery dissections after balloon angioplasty: good outcome without stenting. Heart. 2001; 86 (2): 193-198.

  38. Costa MA, Kozuma K, Gaster AL, van Der Giessen WJ et al. Three dimensional intravascular ultrasonic assessment of the local mechanism of restenosis after balloon angioplasty. Heart. 2001; 85 (1): 73-79.

  39. Wohrle J, Scheller B, Seeger J, Farah A et al. Impact of diabetes on outcome with drug-coated balloons versus drug-eluting stents the BASKET-SMALL 2 trial. JACC Cardiovasc Interv. 2021; 14 (16): 1789-1798.

  40. Zhang JJ, Ye F, Xu K, Kan J et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. Eur Heart J. 2020; 41 (27): 2523-2536.

  41. De Luca G, Suryapranata H, Stone GW, Antoniucci D et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008; 126 (1): 37-44.

  42. Kaltoft A, Kelbaek H, Thuesen L, Lassen JF et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2010; 56 (8): 641-645.

  43. Hamm CW, Dorr O, Woehrle J, Krackhardt F, Ince H, Zeus T et al. A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. EuroIntervention. 2020; 16 (4): e328-e334.

  44. Jensen CJ, Richardt G, Tölg R, Erglis A et al. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. EuroIntervention. 2018; 14 (10): 1096-1103.

  45. Baan J Jr, Claessen BE, Dijk KB, Vendrik J et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE trial. JACC Cardiovasc Interv. 2018; 11 (3): 275-283.

  46. de la Torre Hernández JM, Garcia Camarero T, Lozano Ruiz-Poveda F, Urbano-Carrillo CA et al. Angiography and optical coherence tomography assessment of the drug-coated balloon essential for the treatment of in-stent restenosis. Cardiovasc Revasc Med. 2020; 21 (4): 508-513.

  47. Byrne RA, Neumann FJ, Mehilli J, Pinieck S et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013; 381 (9865): 461-467.

  48. Scheller B, Hehrlein C, Bocksch W, Rutsch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006; 355 (20): 2113-2124.

  49. Unverdorben M, Vallbracht C, Cremers B, Heuer H et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009; 119 (23): 2986-2994.

  50. Xu B, Gao R, Wang J, Yang Y et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014; 7 (2): 204-211.

  51. Wong YTA, Kang DY, Lee JB, Rha SW et al. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial. Am Heart J. 2018; 197: 35-42.

  52. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. 2015; 66 (1): 23-33.

  53. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014; 63 (14): 1378-1386.

  54. Adriaenssens T, Dens J, Ughi G, Bennett J et al. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial. EuroIntervention. 2014; 10 (4): 439-448.

  55. Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the treatment of in-stent restenosis study. Circ Cardiovasc Interv. 2016; 9 (4): e003316.

  56. Jeger RV, Farah A, Ohlow MA, Mangner N et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018; 392 (10150): 849-856.

  57. Latib A, Colombo A, Castriota F, Micari A et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 2012; 60 (24): 2473-2480.

  58. Unverdorben M, Kleber FX, Heuer H, Figulla HR et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? EuroIntervention. 2013; 9 (5): 620-628.

  59. Cortese B, Micheli A, Picchi A, Coppolaro A et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010; 96 (16): 1291-1296.

  60. Cortese B, Di Palma G, Guimaraes MG, Piraino D et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv. 2020; 13 (24): 2840-2849.

  61. Tang Y, Qiao S, Su X, Chen Y et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease: the RESTORE SVD china randomized trial. JACC Cardiovasc Interv. 2018; 11 (23): 2381-2392.

  62. Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention. 2011; 7 Suppl K: K61-K65.

  63. Stella PR, Belkacemi A, Dubois C, Nathoe H et al. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv. 2012; 80 (7): 1138-1146.

  64. López Mínguez JR, Nogales Asensio JM, Doncel Vecino LJ, Sandoval J et al; BABILON Investigators. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results. EuroIntervention. 2014; 10 (1): 50-57.

  65. Berland J, Lefevre T, Brenot P, Fajadet J et al. DANUBIO - a new drug-eluting balloon for the treatment of side branches in bifurcation lesions: six-month angiographic follow-up results of the DEBSIDE trial. EuroIntervention. 2015; 11 (8): 868-876.

  66. Jim MH, Lee MK, Fung RC, Chan AK et al. Six month angiographic result of supplementary paclitaxel-eluting balloon deployment to treat side branch ostium narrowing (SARPEDON). Int J Cardiol. 2015; 187: 594-597.

  67. Kleber FX, Rittger H, Ludwig J, Schulz A et al. Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. Clin Res Cardiol. 2016; 105 (7): 613-621.




2020     |     www.medigraphic.com